Akeso's Third ADC: What "Differentiated" Still Has to Prove & Leads Biolabs Puts 4-1BB Back on the Board

Akeso cleared AK157D1, a B7-H3 antibody-drug conjugate, into Phase 1 in solid tumors — its third differentiated ADC, and a late entry into an already crowded target. Alex and Maya argue whether three assets from one engine is platform depth or correlated risk, and why the dose-escalation ceiling matters more than any early response rate. Also: Leads Biolabs' opamtistomig, a PD-L1/4-1BB bispecific, has an NDA accepted by China's NMPA and is positioned as the first approved 4-1BB-targeting therapy — with liver-monitoring label language as the real open question. Plus Werewolf Therapeutics' reverse merger with Ambros Therapeutics and a $150 million private placement behind neridronate for CRPS-1, and FDA premarket approval of Implantica's RefluxStop implant for GERD.

Alex Mercer and Maya Patel host the Daily Roundup for August 21. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.